Pharmabiz
 

NeuroVive completes patient enrollment in phase III trial on CicloMulsion in Europe

SwedenTuesday, February 18, 2014, 13:00 Hrs  [IST]

NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, has reported that the last of a total of 972 patients have now been enrolled and treated in its ongoing European phase III trial (CIRCUS), in which half of patients received the company’s pharmaceutical CicloMulsion for treating reperfusion injury coincident with myocardial infarction.

“We’ve now reached a major milestone in the European cardiac study on NeuroVive’s product CicloMulsion. The final patient was enrolled and treated in the study on 16 February, and the trial will now be followed up for a one-year period, as it finally closes for data analysis. Enrolment of patients to the trial went well, and we’re satisfied with how it has followed our original plan so far,” commented NeuroVive’s CEO Mikael Brönnegård.

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion (heart attack) and NeuroSTAT (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively.

 
[Close]